Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 11 Issue 2, February 2012

In This Issue

Top of page ⤴

Comment

Top of page ⤴

News and Analysis

  • The US FDA approved 30 new therapeutics last year, including 11 first-in-class agents.

    • Asher Mullard
    News and Analysis
Top of page ⤴

News in Brief

Top of page ⤴

Biobusiness Briefs

Top of page ⤴

Patent Watch

Top of page ⤴

An Audience With

  • RuiPing Dong, head of emerging markets R&D at Merck & Co., discusses the strategy behind the firm's recent US$1.5 billion expansion into China.

    An Audience With
Top of page ⤴

From the Analyst's Couch

  • This article discusses the drug pipeline for neuropathic pain, for which the market is forecast to grow by 50% by 2020.

    • Sarah Nightingale
    From the Analyst's Couch
Top of page ⤴

Fresh from the Pipeline

  • Janus kinase inhibitor approved by the US Food and Drug Administration for the treatment of myelofibrosis.

    • Ruben A. Mesa
    • Uma Yasothan
    • Peter Kirkpatrick
    Fresh from the Pipeline
Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Review Article

  • Inhibitor of apoptosis (IAP) antagonists have recently entered the stage of clinical evaluation for many different types of cancer. Here, Fulda and Vucic review the different approaches that have been used to target IAP proteins, and discuss their translation into therapeutic anticancer strategies.

    • Simone Fulda
    • Domagoj Vucic
    Review Article
  • Here, the authors highlight how RNA-blocking oligonucleotides can redirect alternative splicing, repair defective RNA, restore protein production or downregulate gene expression, and so may be useful for treating disorders such as Duchenne muscular dystrophy, spinal muscular atrophy and β-thalassaemia.

    • Ryszard Kole
    • Adrian R. Krainer
    • Sidney Altman
    Review Article
  • Studies of psychiatric disorders have traditionally focused on emotional symptoms, such as depression, anxiety and hallucinations, but poorly controlled cognitive deficits are also prominent and severely compromise quality of life. This article critically discusses our understanding of the nature and causes of cognitive impairment in psychiatric disorders, and reviews the opportunities and challenges in improving cognition in patients, including the development of more effective translational research approaches.

    • Mark J. Millan
    • Yves Agid
    • Larry J. Young

    Special:

    Review Article
Top of page ⤴

Correspondence

Top of page ⤴

Corrigendum

Top of page ⤴

Erratum

Top of page ⤴

Search

Quick links